In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AstraZeneca buys diabetes business from BMS for $2.7bn up front, plus earn-outs

Executive Summary

After six years of working together and equally sharing global profits from a large joint portfolio, Bristol-Myers Squibb Co. decided to sell its diabetes business to AstraZeneca PLC for $2.7bn in cash. The transaction also includes up to $1.4bn in potential regulatory-, launch- and sales-based earn-outs, plus $225mm in asset transfer payments (related to BMS's Mt. Vernon, Indiana manufacturing facility and Chinese business) and royalties on sales through 2025.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Earnout
    • Full Acquisition
    • Divestiture/Spin-Out
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register